Clinical trial · Interventional
Dextromethorphan in Treating Patients With Fatigue Caused by Cancer
A Pilot Trial to Evaluate the Effects of Dextromethorphan in Patients Suffering From Cancer-Related Fatigue
NCT00176540CI-TRIAL-00004862terminatedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): slow accrual
Summary
Brief summary (as posted)
RATIONALE: Dextromethorphan may help relieve fatigue in patients with cancer. PURPOSE: This clinical trial is studying how well dextromethorphan works in treating patients with fatigue caused by cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Fatigue | — | UNRESOLVED | — |
| Unspecified Adult Solid Tumor, Protocol Specific | Adult Solid Neoplasm | ALIAS | 0.85 |
| Unspecified Childhood Solid Tumor, Protocol Specific | Childhood Solid Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| dextromethorphan hydrobromide | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Efficacy
Secondary outcomes (1)
- measure
- Correlation of the changes in cancer-related fatigue with the levels of plasma homocysteine versus red blood cell folate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 12 Years
- Maximum age
- 75 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of malignancy * Must be undergoing active treatment for malignancy which may include hormonal therapy (e.g., tamoxifen citrate or leuprolide acetate), but not radiotherapy alone * Fatigue score ≥ 4 on a verbal analogue scale of 0 to 10 * No untreated cancer-related anemia PATIENT CHARACTERISTICS: * Hemoglobin \> 10 g/dL * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Able to swallow pills * No known allergy to dextromethorphan hydrobromide * No patients known to be phenotypically poor metabolizers of CYP2D6 * No untreated hypothyroidism PRIOR CONCURRENT THERAPY: * See Disease Characteristics * Prior single-dose inhibitors (e.g., ranitidine or cimetidine) for hypersensitivity prophylaxis allowed * Erythropoietic growth factor therapy of \> 8 weeks duration allowed * No concurrent CYP2D6 inducers or inhibitors * No concurrent monoamine oxidase inhibitors * No other concurrent medications containing dextromethorphan hydrobromide * No concurrent over-the-counter medication, herbal product, vitamin, food supplement, or any other type of special product unless permission to continue use is obtained from the Principal Investigator * No other concurrent anticancer investigational agents or therapies
References
Publications (0)
Data not yet available
No reference posted for this study.